Journal article
Intranasal administration of the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei with the modified heat-labile toxin of Escherichia coli (LTK63) induces a complete protection against malaria challenge.
- Romero JF Department of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland.
- Ciabattini A
- Guillaume P
- Frank G
- Ruggiero P
- Pettini E
- Del Giudice G
- Medaglini D
- Corradin G
- 2008-12-30
Published in:
- Vaccine. - 2009
Adjuvants, Immunologic
Administration, Intranasal
Animals
B-Lymphocytes
Bacterial Toxins
Enterotoxins
Escherichia coli
Escherichia coli Proteins
Female
Malaria
Malaria Vaccines
Mice
Mice, Inbred BALB C
Plasmodium berghei
Protozoan Proteins
T-Lymphocytes
Vaccines, Synthetic
English
Needle-free procedures are very attractive ways to deliver vaccines because they diminish the risk of contamination and may reduce local reactions, pain or pain fear especially in young children with a consequence of increasing the vaccination coverage for the whole population. For this purpose, the possible development of a mucosal malaria vaccine was investigated. Intranasal immunization was performed in BALB/c mice using a well-studied Plasmodium berghei model antigen derived from the circumsporozoite protein with the modified heat-labile toxin of Escherichia coli (LTK63), which is devoid of any enzymatic activity compared to the wild type form. Here, we show that intranasal administration of the two compounds activates the T and B cell immune response locally and systemically. In addition, a total protection of mice is obtained upon a challenge with live sporozoites.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1016/j.vaccine.2008.12.010
- PMID 19111883
- Persistent URL
- https://sonar.ch/global/documents/20081
Statistics
Document views: 21
File downloads: